Merck recently announced the results from the first wave of its Phase 3 development program for a new hepatitis C treatment called Grazoprevir/Elbasvir.
If the treatment is approved, researchers will be submitting a new drug application in 2015.
“Merck is committed to developing an efficacious, well-tolerated therapy suitable for a broad spectrum of patients with HCV (hepatitis C virus),” Merck Research Laboratories Vice President of Infectious Diseases Dr. Eliav Barr said. “We are encouraged by the findings for Grazoprevir/Elbasvir in the C-WORTHy trial and look forward to advancing our broad Phase 3 program, which includes hard-to-cure patients that are of the highest need and least studied to date.”
The study included patients with a variety of degrees of hepatitis C, such as advanced and beginner. The treatment inhibits protease functioning. Patients showed evidence of improved immune responses in just 12 weeks after they completed their therapy.
Many of the treatments responded positively to the treatment. Common side effects associated with the Grazoprevir/Elbasvir administrations included fatigue, headache, nausea, diarrhea and asthenia. Researchers did not see any evidence that would inhibit further study of the new treatments.
The final results of parts A and B of the study were published in The Lancet. The presentation of these results was made at The Liver Meeting in Boston.